David Baker (D Baker)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Topics

Botulinum Toxin

Top Venues

Annals of neurology

Clinical and experimental immunology

Journal of neurology, neurosurgery, and psychiatry

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Valeria Pingitore, Jessica Pancholi, Thomas W Hornsby, Justin Warne, Gareth Pryce, Laura J McCormick, Julia Hill, Gauri Bhosale, Jing Peng, Lydia S Newton, Greg J Towers, Simon J Coles, Ah Wing Edith Chan, Michael R Duchen, Gyorgy Szabadkai, David Baker, David L Selwood
Delocalized quinolinium-macrocyclic peptides, an atypical chemotype for CNS penetration. Science advances 10 (28) (2024)
Valeria Pingitore, Jessica Pancholi, Thomas W Hornsby, Justin Warne, Gareth Pryce, Laura J McCormick, Julia Hill, Gauri Bhosale, Jing Peng, Lydia S Newton, Greg J Towers, Simon J Coles, Ah Wing Edith Chan, Michael R Duchen, Gyorgy Szabadkai, David Baker, David L Selwood
Delocalized quinolinium-macrocyclic peptides, an atypical chemotype for CNS penetration. Science advances 10 (28) (2024)
Johannes M van Noort, David Baker, Markus Kipp, Sandra Amor
The pathogenesis of multiple sclerosis: a series of unfortunate events. Clinical and experimental immunology (2023)
Gareth Pryce, Sofia Sisay, Gavin Giovannoni, David L Selwood, David Baker
Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels. Pharmaceuticals (Basel, Switzerland) 16 (7) (2023)
Anthony Seaton, David Baker, Anna Karin Hedström, L Alfredsson, Klaus Schmierer
Organic solvents and Multiple Sclerosis: the doubled risk dilemma. Occupational medicine (Oxford, England) 73 (6) (2023)
Maddalena Rupnik, David Baker, David L Selwood
Oligodendrocytes, BK channels and the preservation of myelin. F1000Research 10 (2021)
Emma Clare Tallantyre, Nicola Vickaryous, Valerie Anderson, Aliye Nazli Asardag, David Baker, Jonathan Bestwick, Kath Bramhall, Randy Chance, Nikos Evangelou, Katila George, Gavin Giovannoni, Andrew Godkin, Leanne Grant, Katharine E Harding, Aimee Hibbert, Gillian Ingram, Meleri Jones, Angray S Kang, Samantha Loveless, Stuart J Moat, Neil P Robertson, Klaus Schmierer, Martin J Scurr, Sita Navin Shah, Jessica Simmons, Matthew Upcott, Mark Willis, Stephen Jolles, Chu-Yueh Guo
COVID-19 Vaccine Response in People with Multiple Sclerosis. Annals of neurology (2021)
Maddalena Rupnik, David Baker, David L Selwood
Oligodendrocytes, BK channels and remyelination. F1000Research 10 (2021)
Sandra Amor, L Fernández Blanco, David Baker
Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clinical and experimental immunology 202 (2) (2020)
Nicholas G Cunniffe, Khue Anh Vuong, Debbie Ainslie, David Baker, Judy Beveridge, Sorrel Bickley, Patrick Camilleri, Matthew Craner, Denise Fitzgerald, Alerie G de la Fuente, Gavin Giovannoni, Emma Gray, Lorraine Hazlehurst, Raj Kapoor, Ranjit Kaur, David Kozlowski, Brooke Lumicisi, Don Mahad, Björn Neumann, Alan Palmer, Luca Peruzzotti-Jametti, Stefano Pluchino, Jennifer Robertson, Alan Rothaul, Lyndsey Shellard, Kenneth J Smith, Alastair Wilkins, Anna Williams, Alasdair Coles
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 92 (3) (2020)
David Baker, C A K Roberts, G Pryce, A S Kang, M Marta, S Reyes, K Schmierer, G Giovannoni, Sandra Amor
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clinical and experimental immunology 202 (2) (2020)
Sandra Amor, David Baker, Samia Joseph Khoury, Klaus Schmierer, Gavin Giovanonni
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad. Annals of neurology 87 (6) (2020)
Natalia Petrova, Erik Nutma, Daniele Carassiti, James Rs Newman, Sandra Amor, Daniel R Altmann, David Baker, Klaus Schmierer
Synaptic Loss in Multiple Sclerosis Spinal Cord. Annals of neurology 88 (3) (2020)
David Baker, G Pryce, L K James, Klaus Schmierer, G Giovannoni
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. European journal of neurology 27 (2) (2019)
David Baker, Erik Nutma, Helen O'Shea, Anne Cooke, Jacqueline M Orian, Sandra Amor
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model. Annals of clinical and translational neurology 6 (8) (2019)
Nicolas Dubuisson, David Baker, Angray S Kang, Gareth Pryce, Monica Marta, Leo H Visser, Werner E Hofmann, Sharmilee Gnanapavan, Gavin Giovannoni, Klaus Schmierer
Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology 154 (2) (2018)
Bryan Ceronie, Benjamin M Jacobs, David Baker, Nicolas Dubuisson, Zhifeng Mao, Francesca Ammoscato, Helen Lock, Hilary J Longhurst, Gavin Giovannoni, Klaus Schmierer
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. Journal of neurology 265 (5) (2018)
Benjamin Meir Jacobs, Francesca Ammoscato, Gavin Giovannoni, David Baker, Klaus Schmierer
Cladribine: mechanisms and mysteries in multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 89 (12) (2018)
Gareth Pryce, David Baker
Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice. British journal of pharmacology 174 (21) (2017)
David Baker, Gareth Pryce, Cristina Visintin, Sofia Sisay, Alexander I Bondarenko, W S Vanessa Ho, Samuel J Jackson, Thomas E Williams, Sarah Al-Izki, Ioanna Sevastou, Masahiro Okuyama, Wolfgang F Graier, Lesley A Stevenson, Carolyn Tanner, Ruth Ross, Roger G Pertwee, Christopher M Henstridge, Andrew J Irving, Jesse Schulman, Keith Powell, Mark D Baker, Gavin Giovannoni, David L Selwood
Big conductance calcium-activated potassium channel openers control spasticity without sedation. British journal of pharmacology 174 (16) (2017)